{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"47","value":"92"},{"groupId":"OG001","spread":"66","value":"129"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"210"}],"units":"Participants"}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84","value":"171"},{"groupId":"OG001","spread":"115","value":"249"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"187"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"99","value":"227"},{"groupId":"OG001","spread":"144","value":"321"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"163"}],"units":"Participants"}],"title":"Cycle 1 Day 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"117","value":"293"},{"groupId":"OG001","spread":"211","value":"407"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"147"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"130","value":"243"},{"groupId":"OG001","spread":"228","value":"363"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"title":"Cycle 2 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"133","value":"268"},{"groupId":"OG001","spread":"192","value":"381"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"138","value":"256"},{"groupId":"OG001","spread":"245","value":"392"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"206"}],"units":"Participants"}],"title":"Cycle 3 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"151","value":"277"},{"groupId":"OG001","spread":"424","value":"477"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"167"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"139","value":"285"},{"groupId":"OG001","spread":"400","value":"452"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"185"}],"units":"Participants"}],"title":"Cycle 4 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"568","value":"366"},{"groupId":"OG001","spread":"264","value":"470"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"168","value":"306"},{"groupId":"OG001","spread":"275","value":"463"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"180"}],"units":"Participants"}],"title":"Cycle 5 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"165","value":"330"},{"groupId":"OG001","spread":"256","value":"491"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"189","value":"339"},{"groupId":"OG001","spread":"336","value":"523"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"123"}],"units":"Participants"}],"title":"Cycle 7 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"172","value":"348"},{"groupId":"OG001","spread":"336","value":"569"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"100"}],"units":"Participants"}],"title":"Cycle 8 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"193","value":"365"},{"groupId":"OG001","spread":"369","value":"598"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"96"}],"units":"Participants"}],"title":"Cycle 9 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"214","value":"380"},{"groupId":"OG001","spread":"404","value":"593"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"title":"Cycle 12 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"158","value":"354"},{"groupId":"OG001","spread":"361","value":"651"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"Cycle 15 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"140","value":"367"},{"groupId":"OG001","spread":"343","value":"645"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"Cycle 18 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"174","value":"388"},{"groupId":"OG001","spread":"213","value":"668"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 21 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"455","value":"525"},{"groupId":"OG001","spread":"424","value":"651"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Cycle 24 Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"200","value":"566"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Cycle 27 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"210"}],"units":"Participants"}],"description":"Plasma samples were collected at specified timepoints for the assessment of Ctrough.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEAN","populationDescription":"The PK population included all participants with at least 1 available isatuximab concentration post-baseline (whatever the cycle and even if dosing was incomplete) with adequate documentation of dosing and sampling dates and times. Only those participants with data collected at specified timepoints are reported.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Cycle 1 Days 8, 15 and 22, Cycles 2 to 5 Days 1 and 15, Cycles 6, 7, 8, 9, 12, 15, 18, 21, 24 and 27 Day 1","title":"Ctrough of Isatuximab","type":"SECONDARY","unitOfMeasure":"mcg/mL"}